he
New England Journal of Medicine is relaxing its strict conflict-of-interest
rules for authors of certain articles because it cannot find enough experts
without financial ties to drug companies.http://www.nytimes.com/2002/06/13/health/13JOUR.html
he
New England Journal of Medicine is relaxing its strict conflict-of-interest
rules for authors of certain articles because it cannot find enough experts
without financial ties to drug companies.
The change applies to experts who write either editorials or review articles, which are not original studies but overviews of research on a particular drug or treatment. It brings the journal's policy into line with those of other medical publications.
 |
|
|
From 1990 until now, the journal's rule was that nobody who wrote a review article or editorial could have any financial interest in a company that made a product discussed by the article, or in any of its competitors.
Now the journal will forbid such articles by authors who receive payments of $10,000 or more a year as a result of such a stake, or who have stock options or patent interests in those companies.
Original studies will continue to indicate the sponsor of the research and disclose any financial stake the author might have.
ALL INFORMATION, DATA, AND
MATERIAL CONTAINED, PRESENTED, OR PROVIDED HERE IS FOR GENERAL INFORMATION
PURPOSES ONLY AND IS NOT TO BE CONSTRUED AS REFLECTING THE KNOWLEDGE OR OPINIONS
OF THE PUBLISHER, AND IS NOT TO BE CONSTRUED OR INTENDED AS PROVIDING MEDICAL OR
LEGAL ADVICE. THE DECISION WHETHER OR NOT TO VACCINATE IS AN IMPORTANT AND
COMPLEX ISSUE AND SHOULD BE MADE BY YOU, AND YOU ALONE, IN CONSULTATION WITH
YOUR HEALTH CARE PROVIDER.